Harry H. Zhabilov – CSO and Director
Mr. Zhabilov is Chief Scientific Officer of Enzolytics, Inc. He also serves as President & Chief Scientific Officer at Immunotech Laboratories, Inc. He is a Member of the American Institute of Chemical Engineers and a Member of the American Chemical Society. Mr. Zhabilov previously served as Executive Vice President at VG Life Sciences, Inc., Vice Chairman, Secretary & Chief Science Officer at International Technology Systems, Inc., and as Research Scientist at Bulgarian Academy of the Sciences.
Mr. Zhabilov holds a Master’s Degree from the University of Chemical Technology and Metallurgy in Sofia, Bulgaria. He is also a Member of the American Chemical Society and a Member of the American Institute of Chemical Engineers. Mr. Zhabilov served as Chief Scientific Officer for GXP Biopharm, Inc., and Vice President of Research and Development for Viral Genetics, Inc.
Mr. Zhabilov has extensive experience in protein isolation and purification in immunochemistry and biochemistry, along with experience with therapeutic proteins used to treat HIV and cancer. Mr. Zhabilov also has experience in the preparation of applications for a nutraceutical compound/supplement submitted to the FDA. He is also the inventor named in several U.S. patents covering technology related to the immunotherapy of HIV and cancer and an immune enhancer based on the IPF (Inactivated Pepsin Fragment) platform. Mr. Zhabilov has also participated in the management of several clinical trials utilizing therapeutic proteins.
Ronald Moss, MD – Scientific Advisor
Dr. Moss has a Doctor of Medicine Degree from the Chicago Medical School, Chicago, IL, and a Bachelor of Arts degree from SUNY at Stony Brook, NY. His post-graduate training includes courses at the American Association of Immunologists Advanced Immunology Course, HIV Primary Care Mini-Residency Program, Owen Clinic, University of California at San Diego; Allergy and Immunology Fellowship, Clinical Associate in Allergy and Clinical Immunology, Laboratory of Clinical Investigation, NIAID, National Institute of Health, Bethesda MD.
Dr. Moss completed his medical residency in Pediatrics (Research Track) and Assistant Clinical Institute at SUNY in Stony Brook Department of Pediatrics, Stony Brook, NY.
He serves on many corporate boards and has held officer positions in several biotech companies, including:
- Adamis Pharmaceuticals, San Diego, CA, March 2017-Present, Chief Medical Officer
- Ansun Biopharma Inc., San Diego, CA
- Nexbio Inc, San Diego, CA
- Vical Inc., San Diego, CA
- Telos Pharmaceuticals, San Diego, CA
- Merck & Co. Inc., West Point, PA
- The Immune Response Corp., Carlsbad, CA
He has also taught at the UCSD Medical Center, Division of Allergy/Immunology, as Associate Clinical Professor from 1994 to the present.
